Basheer Zada

Basheer Zada is Principal at EcoR1 Capital, LLC, a San Francisco-based biotechnology investment fund. In his current role, he leads due diligence and analysis for value-oriented investments, focusing on innovative biotech companies developing cutting-edge therapeutics. Zada serves as Board Observer for various EcoR1 portfolio companies, including ReCode Therapeutics, and plays a key role in evaluating promising opportunities across the genetic medicines and rare disease therapeutics sectors.

His investment expertise spans the biotechnology and life sciences industries, with particular emphasis on companies advancing mRNA-based therapies, gene correction technologies, and precision delivery platforms. Zada's work supports EcoR1's concentration in breakthrough drug development targeting unmet medical needs, such as rare genetic disorders, respiratory diseases, and next-generation therapeutics.

Prior to joining EcoR1 Capital in 2018 (first as Analyst, then Principal), Zada was Senior Associate at Brace Pharma Capital, focusing on life sciences investments, due diligence, and portfolio management. He holds a master’s degree from Georgetown University and a bachelor's in biology (minors in psychology, medicine & society) from Virginia Tech, establishing a strong foundation in biomedical science and healthcare innovation.